Evidence map›Paper›PMID 33897168›Full record

ArticleUrology annals

Use and outcomes of kidneys from donors with renal angiomyolipoma: A systematic review.

Desiree Garcia Anton, Karthik Kovvuru, Swetha R Kanduri, Narothama Reddy Aeddula, Tarun Bathini, Charat Thongprayoon, Wisit Kaewput, Karn Wijarnpreecha, Kanramon Watthanasuntorn, Sohail Abdul Salim and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology annals. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Desiree Garcia AntonDepartment of Internal Medicine, Division of Nephrology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Karthik KovvuruDepartment of Internal Medicine, Division of Nephrology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Swetha R KanduriDepartment of Internal Medicine, Division of Nephrology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Narothama Reddy AeddulaDepartment of Medicine, Division of Nephrology, Deaconess Health System, Evansville, IN, USA.
Tarun BathiniDepartment of Internal Medicine, University of Arizona, Tucson, AZ, USA.
Charat ThongprayoonDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Wisit KaewputDepartment of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok, Thailand.
Karn WijarnpreechaDivision of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Jacksonville, Florida, USA.
Kanramon WatthanasuntornDepartment of Internal Medicine, Bassett Medical Center, Cooperstown, New York, USA.
Sohail Abdul SalimDepartment of Internal Medicine, Division of Nephrology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Praise MatemaviDepartment of Department of Transplant and Hepatobiliary Surgery, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Pradeep VaitlaDepartment of Internal Medicine, Division of Nephrology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Franco Cabeza RiveraDepartment of Internal Medicine, Division of Nephrology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Wisit CheungpasitpornDepartment of Internal Medicine, Division of Nephrology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
University of Mississippi Medical Center · USBassett Medical Center · USDeaconess Hospital · USMayo Clinic · USPhramongkutklao College of MedicineUniversity of Arizona · USWinnMed · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRenal angiomyolipoma (AML) is the most frequent mesenchymal tumor of the kidney. Although there is a rare possibility of malignant transformation of AML, this risk has not been studied in immunosuppressed patients. The safety of donors with AML and their kidney transplant recipients has not been well established.

methodsA literature search was conducted utilizing MEDLINE, EMBASE, and Cochrane databases from inception through May 15, 2018 (updated on October 2019). We included studies that reported the outcomes of kidney donors with AML or recipients of donor with AML. The protocol for this meta-analysis is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42018095157).

resultsFourteen studies with a total of 16 donors with AML were identified. None of the donors had a diagnosis of tuberous sclerosis complex (TSC), pulmonary lymphangioleiomyomatosis (LAM), or epithelioid variant of AML. Donor age ranged from 35 to 77 years, and recipient age ranged from 27 to 62 years. Ninety-two percent of the donors were female. Only 8% were deceased donor renal transplant. The majority underwent

conclusionThese findings are reassuring for the safety of donors with AML (without TSC or LAM) as well as their recipients without evidence of malignant transformation of AML. As such, this can also positively impact the donor pool by increasing the number of available kidneys.

Indexed as

Donorkidney transplantrenal angiomyolipomarenal transplantationtransplantation

Identifiers

PMID33897168
PMCPMC8052899
OpenAlexW3125962225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.